Egrifta

Egrifta Egrifta (generic name: tesamorelin) is a synthetic growth hormone-releasing factor analog used in the treatment of HIV-associated lipodystrophy. It is specifically designed to reduce excess abdominal fat in HIV-infected patients with lipodystrophy, a condition characterized by abnormal fat distribution.

Mechanism of Action

Egrifta works by stimulating the pituitary gland to release growth hormone, which in turn helps to reduce visceral adipose tissue (VAT) in the abdominal area. The reduction in VAT is beneficial for patients suffering from HIV-associated lipodystrophy, as it can help improve their overall metabolic profile and reduce the risk of cardiovascular diseases.

Indications

Egrifta is indicated for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. It is not indicated for weight loss management in the general population or for the treatment of obesity.

Administration

Egrifta is administered as a subcutaneous injection. The recommended dosage is 2 mg once daily. It is important for patients to follow the administration instructions provided by their healthcare provider to ensure the effectiveness of the treatment.

Side Effects

Common side effects of Egrifta include:

• Injection site reactions (e.g., redness, itching, swelling)
• Joint pain
• Muscle pain
• Swelling in the arms or legs
• Increased blood sugar levels

Patients should report any severe or persistent side effects to their healthcare provider.

Contraindications

Egrifta is contraindicated in patients with:

• Known hypersensitivity to tesamorelin or any of its components
• Active malignancy
• Pregnancy

Precautions

Patients with a history of diabetes or glucose intolerance should use Egrifta with caution, as it may increase blood sugar levels. Regular monitoring of blood glucose levels is recommended during treatment.

Related Pages

• HIV/AIDS
• Lipodystrophy
• Growth hormone
• Pituitary gland
• Cardiovascular disease